|Articles|June 21, 2021

June 2021
Volume 27
Issue 4

Weidner et al, Appendices

Author(s)Susan Weidner, MBA, MS, Michael Diaz, MD, Cass Schaedig

Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology

eAPPENDICES Weidner et al

Articles in this issue

about 5 years ago

Article

Dollars and Sense

about 5 years ago

Article

FDA Panel Votes to Keep 4 of 6 “Dangling Approvals,” in a Sign of Things to Come

about 5 years ago

Article

Observations Regarding the Average Sales Price Reimbursement Methodology

about 5 years ago

Article

Real-World Evidence Is Key to Accelerating Oncology Approvals

about 5 years ago

Article

PATHWAYS: Oncology Care Pathways Launched by Payers: What Are the Trends?

about 5 years ago

Article

about 5 years ago

Article

A Social Worker Leads ACCC, and Her Timing Is Perfect

about 5 years ago

Article

After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Dr Rahul Banerjee | Image Credit: Fred Hutch Cancer Center

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

ByBrooke McCormick,Rahul Banerjee, MD

July 4th 2026

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

ByMaggie L. Shaw,Adam S. Kittai, MD

July 3rd 2026

3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD

BySabrina McCrear,Minhee Kang, PharmD

July 2nd 2026

Integrated VA Care Linked to Equitable Cancer Survival for Black Veterans

ByGiuliana Grossi

July 2nd 2026

Dr Nitin Jain | Image Credit: UT MD Anderson

UCART22 Advances to Phase 2 Following Encouraging Phase 1 Results in R/R B-Cell ALL: Nitin Jain, MD

ByBrooke McCormick,Nitin Jain, MD

July 2nd 2026

Weidner et al, Appendices

Articles in this issue

Related Content

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD

Integrated VA Care Linked to Equitable Cancer Survival for Black Veterans

UCART22 Advances to Phase 2 Following Encouraging Phase 1 Results in R/R B-Cell ALL: Nitin Jain, MD

Trending on AJMC

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Real-World Data Show MASH Progresses Faster Than Trials Suggest

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Weidner et al, Appendices

Articles in this issue

Related Content

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD

Integrated VA Care Linked to Equitable Cancer Survival for Black Veterans

UCART22 Advances to Phase 2 Following Encouraging Phase 1 Results in R/R B-Cell ALL: Nitin Jain, MD

Trending on AJMC

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Real-World Data Show MASH Progresses Faster Than Trials Suggest

emtelligent Turns Unstructured Clinical Data Into Actionable Insights